# Rezolute clinical and financial updates

> Live situation record from CLSTR: https://clstr.news/situations/rezolute-clinical-and-financial-updates
> Updated: 2026-09-24T16:16:39.000Z. Sources: 4. Developments: 2.

Rezolute, Inc. has released its fiscal 2026 financial results and provided updates on its clinical developments regarding the treatment of refractory hypoglycemia caused by hyperinsulinism.

The company is currently conducting the upLIFT Phase 3 study for tumor-related hyperinsulinism. Interim data shows that seven enrolled participants met the responder criterion for the study’s primary endpoint, achieving a complete discontinuation of intravenous glucose requirements after receiving ersodetug. Topline results for this study are anticipated before the end of 2026.

Following these updates, HC Wainwright maintained a ‘buy’ rating for Rezolute (NASDAQ: RZLT) and increased its price target from $5.00 to $10.00.

## Timeline

### 2026-09-24: Rezolute reports fiscal 2026 results and clinical updates

Rezolute, Inc. reported fiscal 2026 results and provided updates on its Phase 3 upLIFT study for hyperinsulinism, while HC Wainwright raised its price target for the company to $10.00.

2 sources. https://clstr.news/cluster/rezolute-reports-fiscal-2026-results-and-clinical-updates

### 2026-09-23: Rezolve AI targets $60 million in annualized savings

Rezolve AI PLC is implementing a $60 million cost-cutting program to reduce cash burn and target positive adjusted EBITDA by mid-2027 through restructuring and external service partnerships.

2 sources. https://clstr.news/cluster/rezolve-ai-targets-60-million-in-annualized-savings

---
Cite as: Rezolute clinical and financial updates. CLSTR, https://clstr.news/situations/rezolute-clinical-and-financial-updates